Close Menu

NEW YORK (360Dx) – PerkinElmer announced today that its Euroimunn Crithidia luciliae test (CLIFT) and CLIFT sensitive immunofluorescence assays have received 510(k) clearance from the US Food and Drug Administration.

CLIFT testing supports the detection of anti-double-stranded DNA, one of the markers for the rheumatic autoimmune disease systemic lupus erythematosus (SLE), PerkinElmer said. The company also noted that the prevalence of anti-dsDNA ranges from 40 percent to 90 percent in lupus patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.